论文部分内容阅读
口服消心痛(Isosorbide dinitrate,ISDN)对心功能不全患者的扩血管作用已为众多研究所肯定。并已确认这一降低肺动脉嵌入压、减轻肺淤血的作用,是由静脉扩张而引起。对重症心功能不全患者来说,用药后可在迅速奏效的同时,获得持续稳定的血管扩张效果。而当血压进一步降低需终止该药的作用时,也很容易找到阻断其效果的药物。在目前临床应用的药物中,酚妥拉明往往引起脉搏增快,硝普纳在日本产量极少,而静脉用的硝酸甘油又存在着被其伍用药物即氯化乙烯吸附等问题。由此可见,很有必要对已在多国应用的ISDN注射剂的有效性、安全性加以鉴定,进而确定其最适宜的使用量。
The vasodilator effect of Isosorbide dinitrate (ISDN) on patients with cardiac insufficiency has been affirmed by many researches. And has confirmed that this lower pulmonary embedding pressure, reduce the role of pulmonary congestion is caused by the expansion of the vein. For patients with severe cardiac insufficiency, medication can be effective at the same time, to obtain sustained and stable vasodilation effect. And when the blood pressure to further reduce the need to stop the role of the drug, it is easy to find the drug blocking its effect. In the current clinical application of drugs, phentolamine often lead to faster pulse, nitroprusside production rarely in Japan, and intravenous nitroglycerin and its existence by its drug Wuzhijia ethylene adsorption and other issues. Therefore, it is necessary to identify the validity and safety of ISDN injection that has been applied in many countries to determine the most suitable dosage.